摘要
目的评价莫西沙星注射液治疗老年中、重度社区获得性下呼吸道感染的疗效和安全性。方法采用随机对照的方法，将64例中、重度社区获得性肺炎（CAP）和慢性支气管炎急性发作（AECB）的老年患者随机分为莫西沙星组和特治星组各32例，莫西沙星组用莫西沙星注射液0．4g，iv，Qd，特治星组用特治星4．5g，iv，Q8h，疗程均为7～14天。结果莫西沙星组痊愈22例，显效6例，总有效率90．3％。特治星组痊愈23例，显效5例，总有效率87．5％，两组比较差异无显著性（P〉0．05）。细菌清除率莫西沙星组为86．7％（13／15），特治星组为92．3％（12／13），两组之间差异无显著性（P〉0．05）。莫西沙星组不良事件发生率15．6％（5／32），仅有l例因严重头晕停药。结论莫西沙星注射液治疗老年社区获得性下呼吸道感染与特治星疗效相当，安全性较好。
Objective To evaluate the efficacy and safety of Moxifloxacin infusion in the treatment of moderate and severe community acquired low respiratory tract infections in olders. Method A randomized trial was comducted ,64 patients with moderate severa CAP or AECB were randomly divided into 2 groups, the study group treated with Moxifloxacin 0. 4 g, iv, Qd for 7 - 14 d;the control group with Tazocin 4. 5 g,iv, Q8 h for 7 - 14 d. Results The total effective rate, and bacterial clearance rate of the study group were 90. 3% ,86.7% ,respectively;while the control group were 87.5% , 92. 3% ,respectively. There was no significant difference. The side effect rate caused by moxifloxacin was 15.6%, only 1 case ceased with treatment because of clizzment. Conclusion Moxifloxacin infusion is efficient and safe.
出处
《中南医学科学杂志》
CAS
2011年第3期320-323,共4页
Medical Science Journal of Central South China
关键词
社区获得性下呼吸道感染
莫西沙星注射液
community-acquired low respiratory tract infections
moxifioxacin infusion
